Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Atsena's gene therapy readout illuminates eye disease efficacy
Atsena is forging ahead with a study that could support a filing for approval in 2028.
Nick Paul Taylor
Oct 7, 2026 9:09am
Merck sees pivotal victory for $3B eye disease prospect
Sep 24, 2026 8:15am
Tarsus pays $450M for Alkeus and its ph. 3 retinal disease drug
Aug 6, 2026 10:30am
IHealthScreen gets FDA nod for dx to spot diabetic retinopathy
Jul 10, 2026 8:55am
Ray shines a light on $125M round targeting genetic eye therapy
Apr 21, 2026 10:33am
J&J hands back failed gene therapy to MeiraGTx
Apr 16, 2026 10:17am
